Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BMS-309403 is an effective, selective and cell-permeable inhibitor of fatty acid binding protein 4 (FABP4) with a Ki of less than 2 nM.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 7,000 | |||
5 mg | 在庫あり | ¥ 11,000 | |||
10 mg | 在庫あり | ¥ 19,500 | |||
25 mg | 在庫あり | ¥ 38,000 | |||
50 mg | 在庫あり | ¥ 49,500 | |||
100 mg | 在庫あり | ¥ 64,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 12,500 |
説明 | BMS-309403 is an effective, selective and cell-permeable inhibitor of fatty acid binding protein 4 (FABP4) with a Ki of less than 2 nM. |
ターゲット&IC50 | FABP3: 250 nM , FABP4:< 2 nM, FABP5: 350 nM |
In vitro | BMS-309403 binds to FABP4 with high affinity and shows over 100-fold selectivity against FABP5 as well as the heart isoform FABP3[1]. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner[2]. BMS-309403 stimulates glucose uptake in C2C12 myotubes in a temporal and dose dependent manner via activation of AMP-activated protein kinase (AMPK) signaling pathway but independent of FABPs[3]. |
In vivo | A 6 week treatment with BMS-309403 improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but does not affect endothelium-independent relaxations. In cultured human microvascular endothelial cells, lipid-induced A-FABP expression is associated with reduced phosphorylated eNOS and NO production and is reversed by BMS-309403[4]. The extent of atherosclerotic lesion area in the proximal aorta is significantly reduced in the BMS-309403-treated group compared with vehicle-treated controls in both the early and late intervention studies[2]. |
分子量 | 474.55 |
分子式 | C31H26N2O3 |
CAS No. | 300657-03-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mM, Heating is recommended.
DMSO: 50 mg/mL (105.36 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BMS-309403 300657-03-8 Metabolism FABP Inhibitor selective oral Fatty acid-binding protein inhibit BMS 309403 endothelial uptake glucose BMS309403 function inhibitor